Company: INTS
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001567264-25-000010
Chunk: 205

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 7
Chunk 205
---
5,647 INVINCIBLE-4 Study (Phase 2 Breast)524 19 505 Other223 4 219 Clinical trial expenses7,077 1,987 5,090 Contract manufacturing657 922 (265)Salaries and benefits related costs1,379 896 483 Consulting143 267 (124)Stock-based compensation1,240 714 526 $10,496 $4,786 $5,710 

Years Ended December 31,20242023ChangeGeneral and administrative expenses:Salaries and benefits related costs$884 $559 $325 Legal fees728 424 304 Accounting fees349 404 (55)Consulting768 430 338 Insurance874 608 266 Other653 424 229 Stock-based compensation1,833 684 1,149 $6,089 $3,533 $2,556 

87

Year Ended December 31, 2024 Compared to Year Ended December 31, 2023

Research and development expenses increased $5.7 million or 119%, and were primarily due to the following:

•Salaries and benefits related costs increased $0.5 million due to two new employee hires in late 2023 and two additional employee hires in early 2024. 

•Clinical trial expenses increased $5.1 million, primarily due to an increase of $5.6 million in the INVINCIBLE-3 Study in 2024, in which we enrolled our first patient in the third quarter of 2024, and to a lesser extent, an increase of $0.5 million in the INVINCIBLE-4 Study, in which we enrolled and dosed our first patient in the fourth quarter of 2024.  These increases were partially offset by a decrease of $1.1 million in our IT-01 Study due to the completion of enrollment in this study in mid-2022 and the completion of study-related costs in 2023.  

•Contract manufacturing decreased by $0.3 million in 2024, as there were fewer INT230-6 batches manufactured compared to 2023. 

•Stock-based compensation increased due to new option awards granted to new employees, and additional option awards granted to employees in 2024, compared to minimal option awards granted in 2023.

General and administrative expenses increased $2.6 million or 72%, and were primarily due